AIMC Topic: Gastrointestinal Agents

Clear Filters Showing 11 to 20 of 20 articles

Machine learning using clinical data at baseline predicts the efficacy of vedolizumab at week 22 in patients with ulcerative colitis.

Scientific reports Aug 12, 2021
Predicting the response of patients with ulcerative colitis (UC) to a biologic such as vedolizumab (VDZ) before administration is an unmet need for optimizing individual patient treatment. We hypothesized that the machine-learning approach with daily...
Proof of Concept Study Adolescent Antibodies, Monoclonal, Humanized Colitis, Ulcerative Gastrointestinal Agents Remission Induction Humans Machine Learning Retrospective Studies Female Aged Aged, 80 and over Young Adult Adult Male Middle Aged
View on PubMed DOI

Expanding the drug discovery space with predicted metabolite-target interactions.

Communications biology Mar 5, 2021
Metabolites produced in the human gut are known modulators of host immunity. However, large-scale identification of metabolite-host receptor interactions remains a daunting challenge. Here, we employed computational approaches to identify 983 potenti...
Cells, Cultured Databases, Factual Inflammatory Bowel Diseases Drug Discovery Gene Expression Profiling Transcriptome Humans Machine Learning Metabolome Anti-Inflammatory Agents Host-Pathogen Interactions Gastrointestinal Agents Data Mining Protein Interaction Maps Ligands Bacteria Molecular Targeted Therapy Signal Transduction Gastrointestinal Microbiome Metabolomics
View on PubMed DOI

What's new in IBD therapy: An "omics network" approach.

Pharmacological research May 16, 2020
The industrial revolution that began in the late 1800s has resulted in dramatic changes in the environment, human lifestyle, dietary habits, social structure, and so on. Almost certainly because this rapid evolution has outpaced the ability of the bo...
Gastrointestinal Agents Diffusion of Innovation History, 21st Century History, 20th Century Humans Forecasting Inflammatory Bowel Diseases Gastroenterology Animals Drug Design Drug Discovery Deep Learning Genomics Systems Biology
View on PubMed DOI

Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver Nov 27, 2017
BACKGROUND: The use of therapeutic drug monitoring has been proposed as a useful tool in the management of patients with loss of response to biological therapy in patients with inflammatory bowel disease.
Remission Induction Humans Adult Drug Monitoring Drug Resistance Prospective Studies Male Antibodies Female Middle Aged Infliximab Aged Time Factors Crohn Disease Young Adult ROC Curve Gastrointestinal Agents Colitis, Ulcerative
View on PubMed DOI

Vedolizumab in inflammatory bowel disease: Real-world outcomes and their prediction with machine learning-the IG-IBD LIVE study.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver Jul 1, 2025
BACKGROUND AND AIMS: Real-world studies on vedolizumab in inflammatory bowel disease (IBD) are often limited by small sample size and short follow-up. In this study, we investigated the 2-year effectiveness and safety of vedolizumab in patients with ...
Humans Machine Learning Inflammatory Bowel Diseases Female Aged Antibodies, Monoclonal, Humanized Colitis, Ulcerative Italy Crohn Disease Gastrointestinal Agents Remission Induction Young Adult Adult Male Middle Aged Treatment Outcome
View on PubMed DOI

Developing a Machine-Learning Prediction Model for Infliximab Response in Crohn's Disease: Integrating Clinical Characteristics and Longitudinal Laboratory Trends.

Inflammatory bowel diseases May 12, 2025
BACKGROUND: Achieving long-term clinical remission in Crohn's disease (CD) with antitumor necrosis factor α (anti-TNF-α) agents remains challenging.
Remission Induction Middle Aged Humans Retrospective Studies Treatment Outcome Machine Learning Longitudinal Studies Female Algorithms Infliximab Young Adult Prognosis Crohn Disease Adult Gastrointestinal Agents Male
View on PubMed DOI

Low Predictability of Readmissions and Death Using Machine Learning in Cirrhosis.

The American journal of gastroenterology Feb 1, 2021
INTRODUCTION: Readmission and death in cirrhosis are common, expensive, and difficult to predict. Our aim was to evaluate the abilities of multiple artificial intelligence (AI) techniques to predict clinical outcomes based on variables collected at a...
Hepatic Encephalopathy Paracentesis Mortality Lactulose beta-Lactams Adrenergic beta-Antagonists Water-Electrolyte Imbalance Patient Readmission Gastrointestinal Hemorrhage Proton Pump Inhibitors Infections Clinical Decision Rules End Stage Liver Disease Rifaximin Middle Aged Severity of Illness Index Cohort Studies ROC Curve Logistic Models Liver Cirrhosis Support Vector Machine Kidney Diseases Hydrothorax Ascites Gastrointestinal Agents Machine Learning Anti-Bacterial Agents Female Reproducibility of Results Aged Male Humans
View on PubMed DOI

The Association Between Arthralgia and Vedolizumab Using Natural Language Processing.

Inflammatory bowel diseases Sep 15, 2018
BACKGROUND: The gut-selective nature of vedolizumab has raised questions regarding increased joint pain or arthralgia with its use in inflammatory bowel disease (IBD) patients. As arthralgias are seldom coded and thus difficult to study, few studies ...
Humans Tumor Necrosis Factor-alpha Prognosis Arthralgia Male Inflammatory Bowel Diseases Antibodies, Monoclonal, Humanized Retrospective Studies Follow-Up Studies Electronic Health Records Immunosuppressive Agents Female Natural Language Processing Adult Gastrointestinal Agents
View on PubMed DOI

Predicting Corticosteroid-Free Biologic Remission with Vedolizumab in Crohn's Disease.

Inflammatory bowel diseases May 18, 2018
BACKGROUND AND AIMS: Vedolizumab (VDZ) is effective for Crohn's disease (CD) but costly and is slow to produce remission. Early knowledge of whether vedolizumab is likely to succeed is valuable for physicians, patients, and insurers.
Antibodies, Monoclonal, Humanized Biological Products C-Reactive Protein Area Under Curve Crohn Disease Gastrointestinal Agents Remission Induction Adrenal Cortex Hormones Adult Male Humans Middle Aged Cohort Studies Machine Learning ROC Curve Female Treatment Outcome Young Adult
View on PubMed DOI

Dosing interval and diagnosis predict infliximab levels in patients with inflammatory bowel disease on maintenance treatment.

Acta gastro-enterologica Belgica Jan 1, 2018
OBJECTIVE: The aim of the study was to identify factors influencing infliximab (IFX) trough levels (TL) in patients with inflammatory bowel disease (IBD).
Antibodies, Monoclonal Humans Infliximab Inflammatory Bowel Diseases Crohn Disease Cross-Sectional Studies Gastrointestinal Agents Treatment Outcome Remission Induction Colitis, Ulcerative
View on PubMed
Popular Topics
Recent Journals